Breaking News
21 hours ago
Vaibhavi M.

Zotefoams admits AMCON to its Global Approved Partner Program, extending regionally stocked, conversion-capable foam supply across the U.S.
Vaibhavi M.

Aurobindo Pharma USA clears FTC review on its $250M Lannett buy, triggering GMP integration across a newly acquired U.S. manufacturing site.
Vaibhavi M.

Eledon's tegoprubart shows a 12 mL/min/1.73 m² eGFR advantage over tacrolimus at 18 months, with zero BPAR events after month six.
Vaibhavi M.

Nuvectis secures ex-China rights to a late-stage CFB inhibitor and a BRAF inhibitor from Haisco, triggering FDA/EMA bridging and CMC alignment work.
Vaibhavi M.
